Does Dr. NITYA ABRAHAM have financial conflicts of interest?

Dr. NITYA ABRAHAM (M.D.) has received a total of $23,141 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $23,141 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. NITYA ABRAHAM?

According to CMS Open Payments data, Dr. NITYA ABRAHAM received funding from SUMITOMO PHARMA AMERICA ($12,183), UROVANT SCIENCES ($4,075), and VALENCIA TECHNOLOGIES CORPORATION ($3,875).

Does Dr. NITYA ABRAHAM receive research grants or speaking fees?

Dr. NITYA ABRAHAM has received $23,141 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. NITYA ABRAHAM

M.D.Real-Time Hydrated

Specialty: Urology, Urogynecology and Reconstructive Pelvic Surgery

Practice Location: BRONX, NY 10461

NPI Number: 1417152349

LIFETIME INDUSTRY VALUE

$23,141

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABRAHAM is a verified Urology, Urogynecology and Reconstructive Pelvic Surgery practitioner based in BRONX, NY.

Between 2021 and 2024, Dr. ABRAHAM had an overall industry promotional and research financial footprint of $23,141 as recorded in the federal CMS Open Payments database.

$23,141 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABRAHAM's primary funding source is SUMITOMO PHARMA AMERICA, which accounts for $12,183 (representing 52.6% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

SUMITOMO PHARMA AMERICA

Rank 1

$12,183

52.6%

UROVANT SCIENCES

Rank 2

$4,075

17.6%

VALENCIA TECHNOLOGIES CORPORATION

Rank 3

$3,875

16.7%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.